EU/3/19/2161

Table of contents

About

On 29 May 2019, orphan designation (EU/3/19/2161) was granted by the European Commission to Worphmed World Orphan Medicines Limited, United Kingdom, for diacerein for the treatment of epidermolysis bullosa.

The sponsorship was transferred to Worphmed World Orphan Medicines Limited, Italy, in August 2019.

Key facts

Active substance
Diacerein
Disease / condition
Treatment of epidermolysis bullosa
Date of first decision
29/05/2019
Outcome
Positive
EU designation number
EU/3/19/2161

Sponsor's contact details

Worphmed World Orphan Medicines Limited
Via Malachia Marchesi De Taddei 21
MI 20146 Milan
Italy 
Tel. +39 0243 3042
E-mail: info@worphmed.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating